Investment Thesis
Advanced Biomed exhibits strong profitability metrics (ROE 68.2%, ROA 59.6%) and exceptional liquidity (8.56x current ratio), but is severely constrained by negative operating cash flow of -1.1M and missing revenue data, indicating potential accounting or operational issues. The 17.1% YoY decline in net income coupled with deteriorating cash generation suggests underlying business challenges that fundamentals alone cannot fully explain.
Strengths
- Exceptional liquidity position with 8.56x current ratio and 2.6M cash reserves
- Very high ROE (68.2%) and ROA (59.6%) indicating efficient asset deployment
- Zero debt (0.00x Debt/Equity) with strong balance sheet structure (9.5M equity vs 1.4M liabilities)
- Positive net income of 6.5M demonstrates profitability in absolute terms
Risks
- Critical red flag: Missing revenue data prevents assessment of actual business performance and margin quality
- Negative operating cash flow (-1.1M) contradicts positive net income, suggesting aggressive accounting or non-cash revenues
- Declining earnings trend with 17.1% YoY net income decline and 14.3% EPS decline indicates deteriorating business momentum
- Data quality concerns with limited available metrics and missing standard income statement components (gross profit, margins)
- Zero insider activity in past 90 days raises concerns about management confidence in company trajectory
Key Metrics to Watch
- Operating cash flow recovery - critical to validate earnings quality and sustainability
- Revenue disclosure and composition - essential to understand if business is generating legitimate top-line growth
- Net income trend stabilization - monitor if 17.1% YoY decline continues or reverses
- Cash burn rate - track if negative OCF continues to erode the 2.6M cash position
Financial Metrics
Revenue
N/A
Net Income
6.5M
EPS (Diluted)
$0.30
Free Cash Flow
-1.1M
Total Assets
10.9M
Cash
2.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
68.2%
ROA
59.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.56x
Quick Ratio
8.56x
Debt/Equity
0.00x
Debt/Assets
12.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T13:54:14.219835 |
Data as of: 2025-12-31 |
Powered by Claude AI